Skip to main content
SpringerLink
Log in

Prognostic factors in multiple myeloma: role of β2-microglobulin and thymidine kinase

  • Original Articles
  • Published:
The clinical investigator Aims and scope Submit manuscript

Summary

Serum β2- microglobulin, serum thymidine kinase, and commonly used prognostic parameters were investigated for their prognostic value in a well-defined group of patients with multiple myeloma (n = 207). Multivariate analysis showed hemoglobin to be the parameter of strongest prognostic value. Only albumin, serum β2-microglobulin and serum thymidine kinase added further prognostic information. When tested for efficiency in recognizing patients with poor (average survival time < 1 year) and good (average survival time > 5 years) prognosis, serum β2-microglobulin was best (80%), followed by total urinary protein (78%), hemoglobin (76%), and albumin (75%).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Adler R, McAuslan BR (1974) Expression of thymidine kinase variants is a function of the replicative state of cells. Cell 2:113–117

    Google Scholar 

  2. Alexanien RA, Balcerzak S, Bonnet JD, Gehan EA, Haut A, Hewlett JS, Monto RW (1975) Prognostic factors in muliple myeloma. Cancer 36:1192–1201

    Google Scholar 

  3. Bard R, Frisch B, Diem H, Mündel M, Fateh-Moghadam A (1989) A bone marrow histology and serum beta-2-microglobulin in multiple myeloma: a new prognostic strategy. Eur J Haematol 43:88–98

    Google Scholar 

  4. Bataille R, Durie BGM, Grenner J, San J (1986) Prognostic factors and staging in multiple myeloma: a reappraisal. J. Clin Oncol 4:80–87

    Google Scholar 

  5. Bataille R, Grenier J, Sany J (1987) Unexpected normal serum beta-2-microglobulin levels in multiple myeloma. Anticancer Res 7:513–516

    Google Scholar 

  6. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A (1992) C-reactive protein and beta-2-microglobulin produce a simple and powerful myeloma staging system. Blood 80:733–737

    Google Scholar 

  7. Bergard I, Bearn AG (1968) Isolation and properties of a low molecular weight b2-globulin occuring in human biological fluids. J of Biol Chem 243:4095–4103

    Google Scholar 

  8. Dacie J (Chairmen) and all other members of the working party (1980) Prognostic features in the third MRC myelomatosis trial. Br J Cancer 42:831

    Google Scholar 

  9. Diem H, Fateh-Moghadam A, Nagel D, Lamerz R (1991) Serum beta-2-microglobulin and thymidine kinase in multiple myeloma: comparison with commonly applied prognostic factors. In: Klapdor R (ed) Tumor associated antigens, oncogenes, receptors, cytokines in tumor diagnosis and therapy at the beginning of the nineties. Zuckschwerdt, Munich, pp 181–184

    Google Scholar 

  10. Durie BGM, Salmon SE (1975) A clinical staging system for multiple myeloma. Cancer 36:842–854

    Google Scholar 

  11. Fateh-Moghadam A, Wilmanns W, Bard R (1986) Zur Diagnostik und Therapie des multiplen Myeloms mit besonderer Berücksichtigung der prognostischen Faktoren. Bayer Internist 8:35–42

    Google Scholar 

  12. Gassmann W, Haferlach T, Schmitz N, Kayser W, Euler HH, Drews J, Löffler H (1984) Analyse prognostischer Faktoren beim Plasmozytom. Klin Wochenschr 62:896–905

    Google Scholar 

  13. Leo R, Boeker M, Peest D, Hein R, Bartl R, Gessner JE, Selbach J, Wacker G, Deicher H (1992) Multiparameter analyses of normal and malignant human plasma cells: CD38++,, CD56+, CD54+, cJg+ is the common phenotype of myeloma cells. Ann Hematol 64:132–139

    Google Scholar 

  14. Luoni R, Ucci G, Riccardi A, Gobbi P, Avato FM, Vignale C, Ascari E (1992) Serum thymidine kinase in monoclonal gammopathies. A prospective study. Cancer 69:1368–1372

    Google Scholar 

  15. Merlini G, Waldenström JG, Jayakar SD (1980) A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients. Blood 55:6

    Google Scholar 

  16. Rabinowitz Y, Wilhite BA (1969) Thymidine salvage pathway and leukemic leucocytes with effect of ATP on enzyme control. Blood 33:759–771

    Google Scholar 

  17. Simonnson B, Källander CFR, Brenning G (1985) Evaluation of serum deoxythymidine kinase as a marker in multiple myeloma. Br J Haematol 61:215–224

    Google Scholar 

  18. Uthmann U, Geisen HP (1981) Beta-2-Mikroglobulin. Heutiger Wissensstand und diagnostische Anwendungsmöglichkeiten. DMW, Jg. 106; Dtsch Med Wochenschr 106:24

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Klinische Chemie, München, Germany

    H. Diem & A. Fateh-Moghadam

  2. Medizinische Klinik II, Klinikum Großhadern, Ludwig-Maximilians-Universität München, München, Germany

    R. Lamerz

Authors
  1. H. Diem
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Fateh-Moghadam
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Lamerz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Diem, H., Fateh-Moghadam, A. & Lamerz, R. Prognostic factors in multiple myeloma: role of β2-microglobulin and thymidine kinase. Clin Investig 71, 918–923 (1993). https://doi.org/10.1007/BF00185604

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00185604

Key words

Search

Navigation